Panelists discuss how increasing utilization management oversight affects physician autonomy and the shared decision-making ...

Panelists discuss how IRA-driven BTK inhibitor price changes could shift payer preferences, necessitating vigilance to ...

Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and ...

Panelists discuss how outdated coverage models lag behind oncology innovation, calling for dynamic policies that reflect ...

Panelists discuss how utilization management policies can delay oncology care and call for reforms that better align ...

Panelists discuss how the Inflation Reduction Act (IRA) introduces landmark changes to drug pricing through its negotiation ...

Panelists discuss how PBMs shape oncology access and stress the need for transparency to align financial control with ...

Panelists discuss how integrating safety and access considerations into oncology policy can create more equitable, ...

Panelists discuss how payers should interpret black box warnings with clinical context to prevent unnecessary restrictions on ...

Panelists discuss how step edits hinder timely cancer treatment and urge policies that prioritize evidence-based access over ...

Patients who used specific immune-boosting herbs before the onset of dermatomyositis had lower rates of autoantibodies, ...

Panelists discuss how outdated coverage decisions can worsen outcomes and increase costs by delaying access to safer, evidence-supported BTK inhibitor therapies.